Forest deal settling US government probe on kickbacks covers civil claims only
This article was originally published in Scrip
Executive Summary
Recent court documents show that Forest Laboratories and the US Department of Justice agreed to settle civil claims arising from a government probe into the marketing of the SSRI antidepressants Celexa (citalopram) and Lexapro (escitalopram) for unapproved paediatric use and the paying of kickbacks to physicians. Now, in a regulatory filing, Forest has disclosed that the pact does not cover an ongoing probe into possible criminal violations related to those products and the hypothyroidism treatment Levothroid.